U.S. markets close in 3 hours 36 minutes

Replimune Group, Inc. (REPL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
34.00-1.31 (-3.71%)
As of 12:21PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close35.31
Open35.26
Bid33.63 x 1000
Ask33.86 x 900
Day's Range33.33 - 36.14
52 Week Range8.58 - 54.85
Volume115,771
Avg. Volume451,236
Market Cap1.581B
Beta (5Y Monthly)2.60
PE Ratio (TTM)N/A
EPS (TTM)-1.75
Earnings DateFeb 04, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est56.30
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Replimune to Present at Three Upcoming Investor Conferences

    WOBURN, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that members from the Replimune management team will present and host one-on-one meetings at the following three virtual investor conferences. H.C. Wainwright Global Life Sciences Conference Date: March 9-10, 2021Pre-Recorded Formal Presentation will be made live: Tuesday, March 9, 2021 at 7:00 am ET Barclays Global Healthcare ConferenceDate: Thursday, March 11, 2021Fireside Chat Presentation Time: 9:10 am ET 33rd Annual Roth ConferenceDate: Wednesday, March 17, 2021Presentation Time: 1:30 pm ET A simultaneous webcast of the fireside chat presentation at the Barclays Global Healthcare Conference will be available in the Investors section of Replimune’s website at www.replimune.com. A replay will be available for approximately 90 days following the conference. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune’s Immulytic™ platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action as well as in standalone indications. For more information, please visit www.replimune.com. Investor Inquiries Chris BrinzeyWestwicke, an ICR Company339.970.2843chris.brinzey@westwicke.com Media InquiriesArleen Goldenberg Verge Scientific Communications917.548.1582agoldenberg@vergescientific.com

  • GlobeNewswire

    Replimune to Present at the SVB Leerink 10th Annual Global Healthcare Conference

    WOBURN, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the SVB Leerink 10th Annual Global Healthcare Conference being held virtually on Wednesday, February 24, 2021 at 8:40 AM ET. A simultaneous webcast will be available in the Investors section of Replimune’s website at www.replimune.com. A replay will be available for approximately 90 days following the conference. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune’s Immulytic™ platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action as well as in standalone indications. For more information, please visit www.replimune.com. Investor Inquiries Chris BrinzeyWestwicke Partners339.970.2843chris.brinzey@westwicke.com Media InquiriesArleen Goldenberg Verge Scientific Communications917.548.1582agoldenberg@vergescientific.com

  • Here's Why We're Not At All Concerned With Replimune Group's (NASDAQ:REPL) Cash Burn Situation
    Simply Wall St.

    Here's Why We're Not At All Concerned With Replimune Group's (NASDAQ:REPL) Cash Burn Situation

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...